AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
For anyone considering PJT Partners, the core belief is that a specialist advisory firm with high returns on equity and disciplined capital return can keep compounding value through cycles, even if headline deal activity moves around. Short term, the bigger swing factors still sit around upcoming results and how resilient advisory fees and margins prove to be, especially after a year where the stock has lagged the broader market despite buybacks and regular dividends. The planned 2026 CFO handover to long‑time insider Arun Kalra looks more like controlled succession than disruption, so it is unlikely to change near term catalysts in a material way. If anything, it reinforces the existing story of seasoned leadership, but investors still need to weigh execution risk in a people‑driven business where recent insider selling has raised questions about confidence at higher valuation multiples.
However, one risk stands out that investors should not overlook. PJT Partners' shares have been on the rise but are still potentially undervalued by 8%. Find out what it's worth.Explore 2 other fair value estimates on PJT Partners - why the stock might be worth just $171.00!
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com